Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT05020067 Completed - Clinical trials for Nasopharyngeal Carcinoma

Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy

Start date: January 12, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical randomized controlled study, the purpose of this study is to assess whether superficial parotid lobe-sparing intensity-modulated radiotherapy (SPLS-IMRT) can decrease the incidence of xerostomia versus conventional IMRT (C-IMRT) in NPC patients.

NCT ID: NCT05011227 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Start date: August 10, 2021
Phase: Phase 2
Study type: Interventional

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

NCT ID: NCT05008471 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study

Start date: April 26, 2021
Phase: N/A
Study type: Interventional

This study will present an advanced equipment of tumor nutrition diagnosis and assesment for nasopharyngeal cancer(NPC) radiotherapy patients in nutritional risk screening, evaluation, diagnosis and directing nutritional intervention, aiming to explore the advantages of the whole nutritional management in acute radiation reaction rate, completion rate of radiotherapy, nutritional status, and quality of life for NPC patients.

NCT ID: NCT04996758 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Start date: October 30, 2021
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy

NCT ID: NCT04995185 Completed - Clinical trials for Nasopharyngeal Carcinoma

18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study

Start date: June 20, 2017
Phase: N/A
Study type: Interventional

This study aims to investigate the use of 18F-FMISO PET in identifying hypoxic subvolume for dose escalation radiotherapy in nasopharyngeal cancer and thus improve local control without significant increase in toxicities.

NCT ID: NCT04992988 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Start date: June 28, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

NCT ID: NCT04978012 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Start date: July 25, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.

NCT ID: NCT04974398 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: August 16, 2021
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT04955886 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: August 2021
Phase: Phase 2
Study type: Interventional

A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

NCT ID: NCT04944914 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.